Metabolic dysfunction-associated steatohepatitis (MASH) is driven by immune-mediated hepatic inflammation, triggered in part by lipid dysregulation, especially elevated palmitic acid, which activates the sphingolipid pathway and raises sphingosine...
Corrie Berk,
DNP, MBA, APRN
Nurse Practitioner, Texas Liver Institute
Resmetirom received accelerated FDA approval in March 2024 for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2-F3),...
Nationwide Study Reveals High Burden of Liver Steatosis and Fibrosis in China’s Adult Population
This nationwide, population-based cross-sectional study aimed to assess the prevalence of liver steatosis and fibrosis in both the general population...
CURATED BY:
Miu Lai (Milly) Ng,
FNP-BC, MPH (Harvard)
During recent decades, the metabolic dysfunction-associated steatohepatitis (MASH) field has witnessed several paradigm shifts, including the recognition of liver fibrosis...
NASH Becoming Leading Cause for Liver Transplantation
Nonalcoholic steatohepatitis (NASH) is rapidly becoming the leading indication for liver transplantation in the US. However, patients with NASH face...
